Long term efficacy of DOTS regimens for tuberculosis: systematic review
Open Access
- 4 February 2008
- Vol. 336 (7642) , 484-487
- https://doi.org/10.1136/bmj.39463.640787.be
Abstract
Objective To identify published studies assessing tuberculosis recurrence after successful treatment with standard short course regimens for six months to determine the strength and sufficiency of evidence to support current guidelines. Design Systematic review. Data sources Medline, Embase, Cochrane clinical trials register, specialist tuberculosis journals, and reference lists. Only English language publications were eligible. Review methods Studies were included irrespective of methodology or quality. Abstracted information included inclusion and exclusion criteria for participants, duration of follow-up, and definitions of treatment success and disease recurrence. The primary outcome was the proportion of successfully treated patients recorded with recurrent tuberculosis during the follow-up period. Results 17 study arms from 16 studies met the inclusion criteria; 10 were controlled clinical trials and six were either studies done under programmatic conditions or observational studies from functioning tuberculosis programmes. Although several clinical trials supported the use of daily treatment regimens, studies reporting tuberculosis recurrence after intermittent regimens were limited. Few studies carried out under routine programmatic conditions reported disease recurrence. Overall there was wide variation in recurrence after successful treatment, ranging from 0% to 14%. Considerable heterogeneity across studies precluded the systematic assessment of factors contributing to tuberculosis recurrence. Conclusions Despite DOTS (directly observed treatment, short course) being implemented for more than 10 years and millions of patients treated for tuberculosis, few studies have assessed the ability of standard DOTS regimens to result in lasting cure for patients treated under routine programmatic conditions.Keywords
This publication has 24 references indexed in Scilit:
- Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trialThe Lancet, 2004
- Scale up: meeting targets in global tuberculosis controlThe Lancet, 2004
- Effects of Human Immunodeficiency Virus Infection on Recurrence of Tuberculosis after Rifampin-Based Treatment: An Analytical ReviewClinical Infectious Diseases, 2003
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of AmericaAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trialThe Lancet, 2002
- Fully intermittent dosing with drugs for treating tuberculosis in adultsCochrane Database of Systematic Reviews, 2001
- Mortality rates and recurrent rates of tuberculosis in patients with smear-negative pulmonary tuberculosis and tuberculous pleural effusion who have completed treatment.2000
- DOT or not? Direct observation of anti-tuberculosis treatment and patient outcomes, Kerala State, India.2000
- Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Algerian working group/British Medical Research Council cooperative study.Published by Elsevier ,1984
- [Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy].1978